R Judd Jessup Sells 1,562 Shares of CorVel (NASDAQ:CRVL) Stock

CorVel Corp. (NASDAQ:CRVL) Director R Judd Jessup sold 1,562 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $70.71, for a total value of $110,449.02. Following the completion of the sale, the director directly owned 117,083 shares in the company, valued at $8,278,938.93. The trade was a 1.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

R Judd Jessup also recently made the following trade(s):

• On Thursday, August 27th, R Judd Jessup sold 1,262 shares of CorVel stock. The stock was sold at an average price of $70.64, for a total transaction of $89,147.68.

CorVel Price Performance

CRVL stock traded up $0.23 during trading on Friday, reaching $69.66. The company had a trading volume of 42,589 shares, compared to its average volume of 218,616. CorVel Corp. has a 52 week low of $44.83 and a 52 week high of $93.45. The business has a 50 day moving average of $63.19 and a 200 day moving average of $58.14. The company has a market cap of $3.55 billion, a P/E ratio of 30.96 and a beta of 0.98.

CorVel (NASDAQ:CRVL) last announced its earnings results on Tuesday, August 4th. The business services provider reported $0.63 EPS for the quarter. The firm had revenue of $259.93 million for the quarter. CorVel had a net margin of 11.72% and a return on equity of 29.92%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CRVL shares. Weiss Ratings raised shares of CorVel from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 16th. Wall Street Zen raised shares of CorVel from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. One equities research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has an average rating of “Hold”.

Institutional Investors Weigh In On CorVel

Hedge funds and other institutional investors have recently made changes to their positions in the business. Corient Private Wealth LP boosted its holdings in shares of CorVel by 43.4% in the second quarter. Corient Private Wealth LP now owns 50,913 shares of the business services provider’s stock worth $3,183,000 after buying an additional 15,414 shares during the last quarter. Amundi bought a new stake in shares of CorVel during the 2nd quarter valued at $386,000. California State Teachers Retirement System increased its stake in shares of CorVel by 7,962.8% in the 2nd quarter. California State Teachers Retirement System now owns 2,350,314 shares of the business services provider’s stock worth $146,942,000 after purchasing an additional 2,321,164 shares in the last quarter. Nykredit A S bought a new position in CorVel in the 2nd quarter worth $80,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in CorVel by 1.4% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 78,890 shares of the business services provider’s stock valued at $4,932,000 after purchasing an additional 1,116 shares in the last quarter. Hedge funds and other institutional investors own 51.36% of the company’s stock.

CorVel Company Profile

CorVel Corporation (NASDAQ: CRVL) is a technology-driven provider of workers’ compensation, liability, and specialty risk management solutions. The company develops and deploys software and data analytics tools to streamline claims administration, medical cost containment, prescription drug management, and provider network access. CorVel’s integrated platform connects employers, insurers, healthcare providers, and injured workers, aiming to improve outcomes and control costs through process automation and real-time decision support.

The company’s product suite includes claims lifecycle management, bill review and negotiation, virtual care and telehealth services, pharmacy benefit management, and independent medical examinations (IMEs).